RYZODEG 70/30
PeakBLASUBCUTANEOUSSOLUTION
Approved
Sep 2015
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYZODEG 70/30 is a premixed insulin combination (70% insulin degludec + 30% insulin aspart) administered as a subcutaneous solution for diabetes management. It combines a long-acting basal insulin with a rapid-acting mealtime component in a single injection. This dual-action formulation simplifies insulin therapy for patients requiring both basal and bolus coverage.
Peak
At peak lifecycle stage with moderate competitive pressure (30), suggesting stable commercial operations and established market presence with potential for managed growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RYZODEG 70/30 offers exposure to mature insulin franchise management, payer negotiations, and established market dynamics within Novo Nordisk's dominant diabetes portfolio. Career growth depends on driving market share gains, managed care strategy, and preparing for eventual biosimilar competition in an increasingly consolidated insulin market.
Brand Manager
Worked on RYZODEG 70/30 at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.